American Society of Hirudotherapy

Eglin C

Potent inhibitor of human leukocyte elastase and cathepsin G — anti-inflammatory protein widely used as research tool.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Eglin C8.1 kDa
Molecular weight (kilodaltons) of Eglin C (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Purified natural compound

Clinical translation limit

Eglin C is a research-grade biochemical tool; its in vitro inhibition of human leukocyte elastase does not establish clinical anti-inflammatory efficacy. No FDA-approved derivative exists.

Ribbon model of two proteins: the large bacterial enzyme subtilisin Carlsberg in green and the small leech inhibitor eglin c in orange, docked at its edge.
Eglin c, an elastase inhibitor from Hirudo medicinalis, in complex with the protease subtilisin Carlsberg (PDB 1CSE, high-resolution X-ray structure). Source: PDBe, EMBL-EBI — PDB 1CSE · PDBe public data (public domain)

Molecular Profile

Category
Proteinase Inhibitor
Evidence tier
Preclinical
Molecular weight
8,100 Da
Source species
Hirudo medicinalis
Discovered
1980 · Seemüller et al.
PDB structures
1ACB1EAI

Biological Targets

  • → leukocyte elastase
  • → cathepsin G
  • → chymotrypsin

Key Citations

  1. Seemüller U et al. (1980), FEBS Lett
  2. Heinz et al. (1992), Biochemistry

Related Proteinase Inhibitor Compounds

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.